Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Míreanna comhchosúla

• MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
  de réir: Ungashe, S, et al.
  Foilsithe / Cruthaithe: (2008)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  de réir: Bekker, P, et al.
  Foilsithe / Cruthaithe: (2007)
• Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
  de réir: Keshav, S, et al.
  Foilsithe / Cruthaithe: (2007)
• PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
  de réir: Bekker, P, et al.
  Foilsithe / Cruthaithe: (2009)
• PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
  de réir: Keshav, S, et al.
  Foilsithe / Cruthaithe: (2009)